Lasting Symptoms After Esophageal Resection (LASER): European Multicenter Cross-sectional Study.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
01 02 2022
Historique:
pubmed: 15 5 2020
medline: 19 2 2022
entrez: 15 5 2020
Statut: ppublish

Résumé

To identify the most prevalent symptoms and those with greatest impact upon health-related quality of life (HRQOL) among esophageal cancer survivors. Long-term symptom burden after esophagectomy, and associations with HRQOL, are poorly understood. Between 2010 and 2016, patients from 20 European Centers who underwent esophageal cancer surgery, and were disease-free at least 1 year postoperatively were asked to complete LASER, EORTC-QLQ-C30, and QLQ-OG25 questionnaires. Specific symptom questionnaire items that were associated with poor HRQOL as identified by EORTC QLQ-C30 and QLQ-OG25 were identified by multivariable regression analysis and combined to form a tool. A total of 876 of 1081 invited patients responded to the questionnaire, giving a response rate of 81%. Of these, 66.9% stated in the last 6 months they had symptoms associated with their esophagectomy. Ongoing weight loss was reported by 10.4% of patients, and only 13.8% returned to work with the same activities.Three LASER symptoms were correlated with poor HRQOL on multivariable analysis; pain on scars on chest (odds ratio (OR) 1.27; 95% CI 0.97-1.65), low mood (OR 1.42; 95% CI 1.15-1.77) and reduced energy or activity tolerance (OR 1.37; 95% CI 1.18-1.59). The areas under the curves for the development and validation datasets were 0.81 ± 0.02 and 0.82 ± 0.09 respectively. Two-thirds of patients experience significant symptoms more than 1 year after surgery. The 3 key symptoms associated with poor HRQOL identified in this study should be further validated, and could be used in clinical practice to identify patients who require increased support.

Sections du résumé

OBJECTIVE
To identify the most prevalent symptoms and those with greatest impact upon health-related quality of life (HRQOL) among esophageal cancer survivors.
BACKGROUND
Long-term symptom burden after esophagectomy, and associations with HRQOL, are poorly understood.
PATIENTS AND METHODS
Between 2010 and 2016, patients from 20 European Centers who underwent esophageal cancer surgery, and were disease-free at least 1 year postoperatively were asked to complete LASER, EORTC-QLQ-C30, and QLQ-OG25 questionnaires. Specific symptom questionnaire items that were associated with poor HRQOL as identified by EORTC QLQ-C30 and QLQ-OG25 were identified by multivariable regression analysis and combined to form a tool.
RESULTS
A total of 876 of 1081 invited patients responded to the questionnaire, giving a response rate of 81%. Of these, 66.9% stated in the last 6 months they had symptoms associated with their esophagectomy. Ongoing weight loss was reported by 10.4% of patients, and only 13.8% returned to work with the same activities.Three LASER symptoms were correlated with poor HRQOL on multivariable analysis; pain on scars on chest (odds ratio (OR) 1.27; 95% CI 0.97-1.65), low mood (OR 1.42; 95% CI 1.15-1.77) and reduced energy or activity tolerance (OR 1.37; 95% CI 1.18-1.59). The areas under the curves for the development and validation datasets were 0.81 ± 0.02 and 0.82 ± 0.09 respectively.
CONCLUSION
Two-thirds of patients experience significant symptoms more than 1 year after surgery. The 3 key symptoms associated with poor HRQOL identified in this study should be further validated, and could be used in clinical practice to identify patients who require increased support.

Identifiants

pubmed: 32404661
pii: 00000658-202202000-00044
doi: 10.1097/SLA.0000000000003917
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e392-e400

Informations de copyright

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest.

Références

Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 2018; 4:1553–1568.
Siegel RL, Miller KD, Jemal A. Cancer statistics 2018. CA Cancer J Clin 2018; 68:7–30.
Anderson LA, Tavilla A, Brenner H, et al. Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5. Eur J Cancer 2015; 51:2144–2157.
Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16:1090–1098.
Alderson D, Cunningham D, Nankivell M, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with esophageal adenocarcinoma (UK MRCOE05): an open-label, randomised phase 3 trial. Lancet Oncol 2017; 18:1249–1260.
Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 2011; 364:2128–2137.
Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med 2019; 380:152–162.
Bouras G, Markar SR, Burns EM, et al. The psychological impact of symptoms related to esophagogastric cancer resection presenting in primary care: a national linked database study. Eur J Surg Oncol 2017; 43:454–460.
McKernan M, McMillan DC, Anderson JR, et al. The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer. Br J Cancer 2008; 98:888–893.
Lagergren P, Fayers P, Conroy T, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-O25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer 2007; 43:2066–2073.
Noordman BJ, Verdam MGE, Lagarde SM, et al. Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial. J Clin Oncol 2018; 36:268–275.
Kauppila JH, Johar A, Lagergren P. Medical and surgical complications and health-related quality of life after esophageal cancer surgery. Ann Surg 2020; 271:502–508.
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85:365–376.
Fayers PM, Aaronson NK, Bjordal K, et al. on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001.
Schandl A, Lagergren J, Johar A, et al. Health-related quality of life 10 years after oesophageal cancer surgery. Eur J Cancer 2016; 69:43–50.
Anandavadivelan P, Lagergren P. Cachexia in patients with oesophageal cancer. Nat Rev Clin Oncol 2016; 13:185–198.
Wikman A, Ljung R, Johar A, et al. Psychiatric morbidity and survival after surgery for esophageal cancer: a population-based cohort study. J Clin Oncol 2015; 33:448–454.
Bouras G, Markar SR, Burns EM, et al. Linked hospital and primary care database analysis of the incidence and impact of psychiatric morbidity following gastrointestinal cancer surgery in England. Ann Surg 2016; 264:93–99.
O’Neill LM, Guinan E, Doyle SL, et al. The RESTORE randomized controlled trial: impact of a multidisciplinary rehabilitative program on cardiorespiratory fitness in esophagogastric cancer survivorship. Ann Surg 2018; 268:747–755.
Reeve JC, Nicol K, Stiller K, et al. Does physiotherapy reduce the incidence of postoperative pulmonary complication following pulmonary resection via open thoracotomy? A preliminary randomised single-blind clinical trial. Eur J Cardiothorac Surg 2010; 37:1158–1166.
Pasquina P, Tramer MR, Granier JM, et al. Respiratory physiotherapy to prevent pulmonary complications after abdominal surgery: a systematic review. Chest 2006; 130:1887–1899.
Maas KW, Cuesta MA, van Berge Henegouwen MI, et al. Quality of life and late complications after minimally invasive compared to open esophagectomy: results of a randomized trial. World J Surg 2015; 39:1986–1993.

Auteurs

Sheraz R Markar (SR)

Department Surgery and Cancer, Imperial College London, UK.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Giovanni Zaninotto (G)

Department Surgery and Cancer, Imperial College London, UK.

Carlo Castoro (C)

Unit of Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology, Padova, Italy.
Division of Upper Gastrointestinal Surgery, Department of Surgery, Humanitas Research Hospital IRCCS, Humanitas University, Rozzano, Milan, Italy.

Asif Johar (A)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Pernilla Lagergren (P)

Department Surgery and Cancer, Imperial College London, UK.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Jessie A Elliott (JA)

Department of Surgery, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland.

Suzanne S Gisbertz (SS)

Department of Surgery, Amsterdam UMC, location AMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.

Christophe Mariette (C)

University Lille, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France.

Rita Alfieri (R)

Unit of Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology, Padova, Italy.

Jeremy Huddy (J)

Department Surgery and Cancer, Imperial College London, UK.

Viknesh Sounderajah (V)

Department Surgery and Cancer, Imperial College London, UK.

Eleonora Pinto (E)

Unit of Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology, Padova, Italy.

Marco Scarpa (M)

Unit of Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology, Padova, Italy.

Fredrik Klevebro (F)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Berit Sunde (B)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Conor F Murphy (CF)

Department of Surgery, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland.

Christine Greene (C)

Department of Surgery, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland.

Narayanasamy Ravi (N)

Department of Surgery, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland.

Guillaume Piessen (G)

University Lille, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France.

Hylke Brenkman (H)

Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.

Jelle P Ruurda (JP)

Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.

Richard Van Hillegersberg (R)

Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.

Sjoerd Lagarde (S)

Department of Surgery, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.

Bas Wijnhoven (B)

Department of Surgery, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.

Manuel Pera (M)

Department of Surgery, University Hospital del Mar, Barcelona, Spain.

José Roig (J)

Department of Surgery, University Hospital del Mar, Barcelona, Spain.

Sandra Castro (S)

Department of Surgery, University Hospital del Mar, Barcelona, Spain.

Robert Matthijsen (R)

Department of Gastrointestinal Surgery, ETZ Tilburg, the Netherlands.

John Findlay (J)

Department of Upper GI Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Stefan Antonowicz (S)

Department of Upper GI Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Nick Maynard (N)

Department of Upper GI Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Orla McCormack (O)

Academic Department of Surgery, Royal Marsden Hospital, London, UK.

Arun Ariyarathenam (A)

Department of Oesophago-Gastric Surgery, Plymouth Hospitals NHS Trust, Plymouth, UK.

Grant Sanders (G)

Department of Oesophago-Gastric Surgery, Plymouth Hospitals NHS Trust, Plymouth, UK.

Edward Cheong (E)

Department of Upper Gastrointestinal Surgery, Norfolk & Norwich Hospitals NHS Trust, Norwich, UK.

Shameen Jaunoo (S)

Department of Upper Gastrointestinal Surgery, Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, UK.

William Allum (W)

Academic Department of Surgery, Royal Marsden Hospital, London, UK.

Jan Van Lanschot (J)

Department of Surgery, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.

Magnus Nilsson (M)

Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.

John V Reynolds (JV)

Department of Surgery, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland.

Mark I van Berge Henegouwen (MI)

Department of Surgery, Amsterdam UMC, location AMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.

George B Hanna (GB)

Department Surgery and Cancer, Imperial College London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH